An immunoperoxidase technique has been utilised for the demonstration of follicle stimulating hormone (FSH), luteinising hormone (LH) and prolactin (PRL) binding sites in normal human ovaries and in a wide range of benign and malignant epithelial tumours of the ovary. The incidence of FSH, LH and PRL binding was, respectively, 32%, 41% and 39% in normal ovaries, 30%, 18.5% and 22.5% in benign epithelial tumours and 51%, 32% and 43% in malignant epithelial neoplasms.
The ovaries are under the trophic control of the pituitary gonadotrophins, follicle-stimulating hormone (FSH) and luteinising hormone (LH): a third pituitary hormone, prolactin, almost certainly has a role, though currently an ill defined one, in the control of ovarian function. The part played by these hormones, particularly the gonadotrophins, in ovarian tumour genesis is currently a matter of considerable interest, largely because of the possibility that hypergonadotrophism may be an aetiological factor in ovarian neoplasia (Beamer, 1981) .
Biochemical studies have demonstrated specific receptors for gonadotrophins and prolactin in the normal human ovary (Poindexter et al., 1979; McNeilly et al., 1980; Kammerman, 1980 Kammerman, , 1981 Rao et al., 1981) and in ovarian neoplasms (Davy et al., 1977; Kammerman et al., 1980 Kammerman et al., , 1981 Rajaniemi et al., 1981a) whilst immunoperoxidase techniques have been used to demonstrate gonadotrophin-binding sites in rat gonads (Petrusz & Uhlarik, 1973; Petrusz, 1974; Childs et al., 1978; Rajaniemi et al., 1981b) and prolactin-binding sites in human prostate gland (Witorsch, 1978) and in normal and neoplastic human breast tissue (Paterson et al., 1982; Purnell et al., 1982; Dhadley & Walker, 1983 ).
There have not, to the best of our knowledge, been any reported immunohistochemical studies of gonadotrophin and prolactin binding sites in normal human ovaries or in ovarian neoplasms: the aims of this study were (a) to repair this deficiency, (b) to determine if the pattern of gonadotrophin and prolactin binding in ovarian epithelial neoplasms differs in benign, borderline and malignant tumours and (c) to determine if there is any relationship between the presence of gonadotrophin and prolactin binding sites and the histological type of ovarian neoplasm, the degree of differentiation of malignant tumours and the presence or absence of metastases.
Materials and methods

Material
Tissue from 99 normal ovaries and from 141 ovarian neoplasms was studied (Table I) , all tissues being obtained either from surgical specimens or from biopsy material received in the Department of Pathology, St. Mary's Hospital, Manchester. In 100 of the cases the material was received fresh: one portion was snap frozen in liquid nitrogen whilst the remainder was fixed in formalin. From the other 140 cases only formalin-fixed tissue was available.
Pituitary tissue was used as a positive tissue control, and lung, myocardium and skeletal muscle, serving as negative tissue controls, were obtained from autopsy material. Rabbit antisera to the beta-subunits of LH and FSH and to PRL, FSH and LH were partly donated by NIAMDD and were also purchased from Calbiochem-Behring Corp. FSH, LH and PRL were purchased from Calbiochem-Behring Corp. Swine anti-rabbit immunoglobulin antiserum, normal rabbit serum, normal swine serum and rabbit peroxidase-l-antiperoxidase (PAP) were obtained from Dako Immunoglobulins Ltd. whilst diaminobenzidine tetrahydrochloride was purchased from Aldrich Chemical Co.
Methods
Serial 5pm frozen and paraffin-embedded sections were prepared by routine laboratory procedures and assayed immunocytochemically for detection of hormone binding using the double PAP method as previously reported (Al Timimi et al., 1985) . In brief, paraffin sections were deparaffinised in xylene and hydrated through graded alcohols. Endogenous peroxidase activity was blocked by immersing the section in a solution of 1% wt/vol hydrogen peroxide in methanol for 1 h: the sections were then washed for 1 h in Tris buffered saline (TBS) at pH 7.6 and subsequently incubated with a 1: 5 dilution of normal swine serum for 5 min in order to reduce non-specific background staining. The sections were then incubated with the appropriate hormone (FSH, LH or PRL), at concentrations of 10-20pgml-1 in TBS (pH 7.5) with (vol/vol) 1% absolute ethanol, overnight at 4°C in a moist chamber. Following this the sections were washed and fixed for 5min in 1% paraformaldehyde to stabilise the hormones at their binding sites. In some sections from each case the step of addition of hormones was omitted to demonstrate endogenous in vivo hormone binding. The sections were then washed with TBS and incubated sequentially with the following antisera for the times indicated: (i) rabbit anti-FSH (1:300), rabbit anti-LH (1:300) or rabbit anti-PRL (1:200) for 24 h at 4°C: (ii) swine anti-rabbit immunoglobulin (SAR, diluted 1:50, for 15min: (iii) PAP soluble complex (1:100) for 30min: (iv) SAR (1:100) for 15min: (v) PAP (1:100) for 15 min. Unless noted otherwise all incubations were conducted in a moist chamber at room temperature. The sections were washed with TBS (pH 7.6) after exposure to the primary antisera, SAR and PAP.
The bound hormones were visualised by incubating the slides for 5min with a filtered freshly prepared solution of 50mg DAB in 100ml of TBS (pH 7.6) to which was added 0.02 ml of 30 vol hydrogen peroxide per 100 ml of substrate solution. The slides were then counterstained with haematoxylin, dehydrated to xylene and coverslipped with permount.
Specificity controls
Tissue controls Normal pituitary glands were used as positive controls for FSH, LH and PRL staining whilst sections from lung, myocardium and skeletal muscle were used as negative tissue controls.
Method controls In every staining run one component of the sequential staining reaction was omitted from at least one section. Usually the primary antiserum was replaced by normal rabbit serum but sometimes SAR or PAP was replaced by diluent buffer or DAB by TBS.
Absorption controls These were prepared by mixing a purified hormone preparation with the antiserum to this hormone for 24 h at 4°C prior to the inclusion of the antiserum in the IP procedure.
Quantitation of results
The degree of binding was scored on the basis of the proportion of positively staining cases from + to + + +, an admittedly arbitrary and subjective grading system but nevertheless one which, in practice, gave reproducible results.
Statistical analysis
All the results obtained were subjected to a chisquare test, a probability level of P<0.05, being taken to represent statistical significance.
Results
A positive reaction for hormone binding was seen as a brown granular precipitate after addition of DAB. All the sections of presumably positive pituitary tissue controls for LH, FSH and PRL gave the expected positive result (Figure la formalin fixed and paraffin embedded tissues were identical to those seen in frozen sections, both in respect of the number of positively staining cells and the strength of the staining reaction.
Endogenous in vivo binding of gonadotrophins and prolactin was seen in many sections of both normal and neoplastic ovarian tissue but the staining was generally weak and occurred in the same sites that subsequently showed binding of exogenous gonadotrophins and prolactin under in vitro conditions (Figure 2) .
The incidences of a positive reaction for binding of FSH, LH and PRL in both normal and neoplastic ovarian tissue are shown in Table II . The relationship between the presence of these binding sites and the menopausal status of the patient, the histological type of tumour, the histological grade of the neoplasm and the presence or absence of metastases are detailed in Tables II-V.
In the normal ovaries FSH binding was seen in the granulosa cells of the pre-antral and antral follicles (Figure 2a ) but was minimal or absent in atretic follicles. The binding sites in the reactive granulosa cells appeared to be localised in the cytoplasm or, in a minority of cases, in the nucleus. Binding of FSH to stromal cells was also seen. LH binding was seen in the granulosa cells of large antral follicles and in the stromal cells. Within the granulosa cells the pattern of binding was similar to that of FSH binding though LH binding appeared to be purely cytoplasmic in the stromal cells. LH binding was also seen in both granulosa cells and thecal cells of corpora lutea. PRL binding followed the general pattern of LH binding but a notably strong reaction was observed in the luteinised cells of corpora lutea (Figure 3) .
Of the 111 epithelial ovarian tumours studied, 46 (41.4%) stained positively for FSH binding, 29 (26%) for LH binding and 38 (34%) for PRL binding. As compared with normal ovarian tissue or with benign epithelial tumours there was a statistically significant excess of FSH binding in malignant epithelial tumours whilst the incidence of PRL binding was significantly greater in malignant epithelial ovarian tumours than in benign epithelial neoplasms of the ovary. There was no significant correlation between the presence of hormone binding sites and the menopausal status of the patient, the histological type of epithelial ovarian tumour, the degree of malignancy of ovarian epithelial tumours or with the presence or absence of metastatic disease.
Hormone binding sites were not demonstrated in mature ovarian teratomas or in metastatic tumours of the ovary but in sex cord stromal tumours, FSH binding was demonstrable in 37% of cases, LH binding in 42% and PRL binding in 31.5%.
Within ovarian neoplasms DAB granules were seen principally in the cytoplasm of the neoplastic epithelial cells (Figures 4 and 5 ) but in some cases staining was restricted to focal areas of the tumour cell membrane whilst in others staining was predominantly nuclear. A striking feature of the pattern with ovarian neoplasms was the marked heterogeneity of the tumour cells for binding sites to all the studied hormones, strongly staining cells being admixed with cells which gave totally negative staining reactions ( Figure 6 ). 
Discussion
In this study FSH, LH and PRL binding sites have been demonstrated by immunohistochemical techniques in a considerable proportion of normal human ovaries and in many ovarian epithelial tumours. Our finding that formalin-fixed, paraffin embedded tissue sections can be used to detect both in vivo and in vitro binding sites is in accord with the results of other immunohistochemical studies of gonadotrophin binding sites in rat testes (Childs et al., 1978; Rajaniemi et al., 1981b) and rat ovaries (Petrusz & Uhlahrik, 1973; Petrusz, 1974; Petrusz & Sar, 1978) and with studies of PRL binding sites in rat ovaries (Nolin, 1978 (Nolin, , 1980 Dunaif et al., 1977 Dunaif et al., , 1982 in human, dog and rat prostatic tissue (Eletreby & Mahrous, 1979; Witorsch, 1978 Witorsch, , 1979a Witorsch, , 1979b Purnell et al., 1982) , dog breast tissue The same tumour as shown in Figure 5a : initial PRL incubation was omitted in order to show in vivo binding of endogenous PRL (IP x 500).
(a) Figure 6 A Brenner tumour stained for FSH-binding. There is a markedly heterogenous pattern of tumour cell staining (IP x 630). (Eletreby & Mahrous, 1979) and mouse adrenal gland (McDonough & Ewig, 1982) . Dhadley and Walker (1983) were, however, unable to detect PRL binding in paraffin-embedded sections of human breast tissue and advocated the sole usage of frozen sections: it appears therefore that the stability of binding sites for PRL varies from organ to organ. The validity of immunoperoxidase techniques for the demonstration of hormone receptor sites has been subjected to stringent criticism (Zehr et al., 1981; McCarty et al., 1981; Underwood, 1983) but we have elsewhere countered these arguments (Al-Timimi et al., 1985) and have pointed out that immunohistochemical techniques appear to demonstrate hormone binding to specific recognition sites. It could, of course, be argued that the technique used here simply demonstrates sites of non-specific absorption but this would leave open the question as to why such non-specific binding is not seen in non-target tissues. The specific recognition sites shown by immunohistochemical techniques probably do not coincide in their entirety with the receptors measured by biochemical cytosol assays but nevertheless given an equally characteristic picture of the hormonebinding capacity of particular cells and tissues. This is emphasised by a comparison of our findings with those reported by workers using biochemical techniques to demonstrate FSH, LH and PRL receptors for our results are very similar to those obtained by Kammerman (1980 ), Kammerman et al. (1981 and Rajaniemi et al. (1981) . Our results in respect to PRL binding in normal human ovarian tissue are also in accord with previous biochemical studies (Poindexter et al., 1979; McNeilly et al., 1980) : there have been no previous reports of the frequency of PRL binding in ovarian enithelial tumours but our results for neoDIasms of this type correspond very closely to reports of the incidence of biochemically assayable PRL receptors in human breast carcinomas (Di Carlo et al., 1980; Turcot-Lemay & Kelly, 1982) .
In this study those ovarian epithelial neoplasms showing a positive reaction for FSH, LH or PRL binding showed a striking degree of heterogeneity with strongly staining cells admixed with totally negative cells. This was not unexpected but in addition, however, ovarian adrenocarcinomas were heterogenous in respect to the cellular localisation of bound gonadotrophins and prolactin. A similar heterogeneity of cellular staining pattern has previously been noted in rat prostatic carcinomas (Witorsch, 1979a,b) , in human prostatic carcinoma (Purnell et al., 1982) and in human breast carcinomas (Paterson et al., 1982; Purnell et al., 1982; Dhadley & Walker, 1983) . This variable pattern of staining for gonadotrophin and prolactin binding sites suggests that there may be subpopulations of ovarian carcinoma cells with differing hormone binding abilities or under different hormonal controls. Until recently the dogma has been that the binding sites for gonadotrophins, like those for other protein hormones, are exclusively present in the limiting membranes of target tissue cells. Recent studies have, however, contradicted this traditional belief by showing that not only the plasma membranes but also various intracellular organelles contain gonadotrophin receptors (Rao et al., 1981; Rajandran & Menon, 1983) . Immunoperoxidase studies have also shown that intracellular prolactin is present in rat ovaries (Dunaif et al., 1977 (Dunaif et al., , 1982 Nolin, 1978 Nolin, , 1980 and in human breast and prostatic tissue (Purnell et al., 1982) whilst intracellular gonadotrophins have been demonstrated in rat ovary (Petrusz & Uhlarik, 1973; Petrusz, 1974; Petrusz & Sar, 1978) and human prostate (Sibley, 1981) .
Our findings in respect to the clinical or prognostic value of the demonstration of gonadotrophin and prolactin binding sites were disappointing. It would have been expected that well differentiated epithelial tumours were more likely to have demonstrable hormone binding sites than would poorly differentiated neoplasms but this proved not to be the case. It is worth noting, however, that the strength of the reaction obtained did vary considerably with the degree of tumour differentiation. Thus, the staining reaction for FSH binding was strong (+ + +) in 54% of well differentiated tumours showing binding for this hormone but attained this degree of staining intensity in only 22% of positively reacting neoplasms which were poorly differentiated. The equivalent figures for LH binding were 37.5 and 0% whilst those for prolactin binding were 36 and 0%. These figures suggest that whilst the number of cells with hormone binding sites does not alter with decreasing differentiation of an ovarian tumour the number of binding sites in each individual cell does, there being a progressive decrease in staining intensity with decreasing degrees of cellular differentiation.
The incidence of FSH binding was significantly higher in malignant epithelial neoplasms than in either normal ovaries or benign epithelial neoplasms. This observation can, of course, be interpreted in several ways but would certainly tend to support the view that FSH plays a role in ovarian tumourigenesis. It has traditionally been thought, however, that if FSH does indeed play a role in this respect it does so by increasing the number of inclusion cysts derived from the ovarian surface epithelium rather than by promoting malignant change in such cysts. The observation that an increased incidence of FSH-binding was noted in malignant but not in benign epithelial neoplasms of the ovary would tend to argue against this concept.
